TY - JOUR
T1 - Sputum microscopy with fluorescein diacetate predicts tuberculosis infectiousness
AU - Datta, Sumona
AU - Sherman, Jonathan M.
AU - Tovar, Marco A.
AU - Bravard, Marjory A.
AU - Valencia, Teresa
AU - Montoya, Rosario
AU - Quino, Willi
AU - D'Arcy, Nikki
AU - Ramos, Eric S.
AU - Gilman, Robert H.
AU - Evans, Carlton A.
N1 - Funding Information:
Financial support. This work was supported principally by the Wellcome Trust Fellowship 105788/Z/14/Z. Specific activities and researchers were also supported by the Wellcome Trust (award numbers 057434/Z/99/Z, 070005/Z/02/Z, and 078340/Z/05/Z); the Joint Global Health Trials Consortium of the Medical Research Council, UK; UK-AID and the Wellcome Trust (award number MR/K007467/1); the Bill & Melinda Gates Foundation (award number OPP1118545); the Imperial College Biomedical Research Centre; the World Health Organization; and the charity Innovation for Health and Development (IFHAD). Potential conflicts of interest. All authors: No potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Publisher Copyright:
© The Author 2017.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Background: Sputum from patients with tuberculosis contains subpopulations of metabolically active and inactive Mycobacterium tuberculosis with unknown implications for infectiousness. Methods: We assessed sputum microscopy with fluorescein diacetate (FDA, evaluating M. tuberculosis metabolic activity) for predicting infectiousness. Mycobacterium tuberculosis was quantified in pretreatment sputum of patients with pulmonary tuberculosis using FDA microscopy, culture, and acid-fast microscopy. These 35 patients' 209 household contacts were followed with prevalence surveys for tuberculosis disease for 6 years. Results: FDA microscopy was positive for a median of 119 (interquartile range [IQR], 47-386) bacteria/μL sputum, which was 5.1% (IQR, 2.4%-11%) the concentration of acid-fast microscopy-positive bacteria (2069 [IQR, 1358-3734] bacteria/μL). Tuberculosis was diagnosed during follow-up in 6.4% (13/209) of contacts. For patients with lower than median concentration of FDA microscopy-positive M. tuberculosis, 10% of their contacts developed tuberculosis. This was significantly more than 2.7% of the contacts of patients with higher than median FDA microscopy results (crude hazard ratio [HR], 3.8; P =.03). This association maintained statistical significance after adjusting for disease severity, chemoprophylaxis, drug resistance, and social determinants (adjusted HR, 3.9; P =.02). Conclusions: Mycobacterium tuberculosis that was FDA microscopy negative was paradoxically associated with greater infectiousness. FDA microscopy-negative bacteria in these pretreatment samples may be a nonstaining, slowly metabolizing phenotype better adapted to airborne transmission.
AB - Background: Sputum from patients with tuberculosis contains subpopulations of metabolically active and inactive Mycobacterium tuberculosis with unknown implications for infectiousness. Methods: We assessed sputum microscopy with fluorescein diacetate (FDA, evaluating M. tuberculosis metabolic activity) for predicting infectiousness. Mycobacterium tuberculosis was quantified in pretreatment sputum of patients with pulmonary tuberculosis using FDA microscopy, culture, and acid-fast microscopy. These 35 patients' 209 household contacts were followed with prevalence surveys for tuberculosis disease for 6 years. Results: FDA microscopy was positive for a median of 119 (interquartile range [IQR], 47-386) bacteria/μL sputum, which was 5.1% (IQR, 2.4%-11%) the concentration of acid-fast microscopy-positive bacteria (2069 [IQR, 1358-3734] bacteria/μL). Tuberculosis was diagnosed during follow-up in 6.4% (13/209) of contacts. For patients with lower than median concentration of FDA microscopy-positive M. tuberculosis, 10% of their contacts developed tuberculosis. This was significantly more than 2.7% of the contacts of patients with higher than median FDA microscopy results (crude hazard ratio [HR], 3.8; P =.03). This association maintained statistical significance after adjusting for disease severity, chemoprophylaxis, drug resistance, and social determinants (adjusted HR, 3.9; P =.02). Conclusions: Mycobacterium tuberculosis that was FDA microscopy negative was paradoxically associated with greater infectiousness. FDA microscopy-negative bacteria in these pretreatment samples may be a nonstaining, slowly metabolizing phenotype better adapted to airborne transmission.
KW - Fluorescein diacetate
KW - Infectiousness
KW - Microscopy
KW - TB
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85030611828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030611828&partnerID=8YFLogxK
U2 - 10.1093/infdis/jix229
DO - 10.1093/infdis/jix229
M3 - Article
C2 - 28510693
AN - SCOPUS:85030611828
SN - 0022-1899
VL - 216
SP - 514
EP - 524
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 5
ER -